Compare UAA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | VERA |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | 362 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2005 | 2021 |
| Metric | UAA | VERA |
|---|---|---|
| Price | $4.90 | $28.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 26 | 14 |
| Target Price | $6.24 | ★ $71.36 |
| AVG Volume (30 Days) | ★ 8.5M | 1.5M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,966,370,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | $725.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $26.38 |
| 52 Week High | $8.15 | $56.05 |
| Indicator | UAA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 40.99 |
| Support Level | $4.74 | $26.92 |
| Resistance Level | $5.28 | $36.95 |
| Average True Range (ATR) | 0.28 | 1.68 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 28.74 | 4.97 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.